20-037 / 20-393 - S1826 - Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaStatus: open
S1826 - A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Treatment for - Classical Hodgkin Lymphoma
This randomized phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of nivolumab or brentuximab vedotin to combination chemotherapy may shrink the cancer or extend the time without disease symptoms coming back.
SponsorsThis trial is sponsored by National Cancer Institute (NCI).
Providers Associated With This Trial
- Hamayun Imran, M.D.Pediatric Hematologist/OncologistProfessor of Pediatrics
- Felicia L. Wilson, M.D.Pediatric Hematologist/OncologistProfessor of Pediatrics
- Preethi Marri, M.D.Pediatric Hematology and OncologyAssistant Professor of Pediatrics
- Omar Alkharabsheh, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology